Literature DB >> 1850674

Changes in cardiac angiotensin converting enzyme after myocardial infarction and hypertrophy in rats.

C I Johnston1, V Mooser, Y Sun, B Fabris.   

Abstract

1. Cardiac angiotensin-converting enzyme (ACE) is localized in high concentration in cardiac valves, coronary vessels, right and left atrium and right and left ventricle. 2. Cardiac ACE is functionally active in converting angiotension I to angiotensin II. 3. The level of cardiac ACE measured by radioinhibitor binding or by quantitative in vitro autoradiography was greatly increased after experimental myocardial infarction in the rat. The increase was greatest in the fibrous scar tissue of the free left ventricular wall infarct, but there were also significant increases in the ACE concentration in the four chambers of the heart. 4. Treatment with enalapril for 4 weeks following coronary ligation inhibited cardiac ACE, including the high levels found in the scar in the left ventricular free wall. 5. There was a close relationship between the systolic blood pressure and left ventricular mass in several models of experimental hypertension, despite varying degrees of activation of the renin-angiotensin system. However no relationship between the degree of left ventricular hypertrophy and changes in cardiac ACE could be determined. 6. Inhibition of cardiac ACE may contribute to the beneficial effect of ACE inhibitors in cardiac hypertrophy and remodelling, and may play a part in the cardioprotective role of ACE inhibitor.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1850674     DOI: 10.1111/j.1440-1681.1991.tb01417.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  7 in total

1.  ACE inhibitors after myocardial infarction.

Authors:  M K Vannan; D J Taylor; M M Webb-Peploe; M A Konstam
Journal:  BMJ       Date:  1993-02-27

2.  Changes in fatty acid compositions of myocardial lipids in rats with heart failure following myocardial infarction.

Authors:  Y Nasa; Y Sakamoto; A Sanbe; H Sasaki; F Yamaguchi; S Takeo
Journal:  Mol Cell Biochem       Date:  1997-11       Impact factor: 3.396

Review 3.  Adaptive and genetic alterations of the renin angiotensin system in cardiac hypertrophy and failure.

Authors:  S R Holmer; H Schunkert
Journal:  Basic Res Cardiol       Date:  1996       Impact factor: 17.165

4.  Ramipril prevents left ventricular hypertrophy with myocardial fibrosis without blood pressure reduction: a one year study in rats.

Authors:  W Linz; J Schaper; G Wiemer; U Albus; B A Schölkens
Journal:  Br J Pharmacol       Date:  1992-12       Impact factor: 8.739

5.  Ramiprilat increases bradykinin outflow from isolated hearts of rat.

Authors:  C R Baumgarten; W Linz; G Kunkel; B A Schölkens; G Wiemer
Journal:  Br J Pharmacol       Date:  1993-02       Impact factor: 8.739

6.  Neurohumoral and hemodynamic effects of ibopamine in a rat model of chronic myocardial infarction and heart failure.

Authors:  D J van Veldhuisen; W H van Gilst; B J de Smet; P A de Graeff; E Scholtens; H Buikema; A R Girbes; H Wesseling; K I Lie
Journal:  Cardiovasc Drugs Ther       Date:  1994-04       Impact factor: 3.727

7.  Cardiomyopathy development protection after myocardial infarction in rats: Successful competition for major dihydropyridines' common metabolite against captopril.

Authors:  Katarzyna A Mitręga; Adrianna M Spałek; Jerzy Nożyński; Maurycy Porc; Magdalena Stankiewicz; Tadeusz F Krzemiński
Journal:  PLoS One       Date:  2017-06-21       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.